VEGF production by primary human renal proximal tubular cells: Requirement of HIF-1, PI3-kinase and MAPKK-1 signaling

Cellular Physiology and Biochemistry

Volumn 15, Issue 1-4, 2005, Pages 99-108

  Hellwig Bürgel, Thomas ^a,e   Stiehl, Daniel P ^a   Katschinski, Dörthe M ^a,b   Marxsen, Jan ^a   Kreft, Burkhard ^c,d   Jelkmann, Wolfgang ^a  

^a University of Lübeck   (United Kingdom)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Campus Lübeck ^*  (Germany)

^d Clinic for Nephrology   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Erk1 2 (p42 44 mitogen activated protein kinase); Hypoxia inducible factor 1; Interleukin 1; Phosphatidylinositol 3 kinase; Renal tubules; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN;

ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY CELL CULTURE; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 12444324520     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083642     Document Type: Article

References (40)

1. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
2. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
3. Metzen E, Ratcliffe PJ: HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004;385:223-230.
4. Hellwig-Burgel T., Rutkowski K, Metzen E, Fandrey J, Jelkmann W: Interleukin-1β and tumor necrosis factor-a stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999;94:1561-1567.
5. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B: Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1a/ARNT. EMBO J 1998;17:5085-5094.
6. Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1a in vascular smooth muscle cells. J Biol Chem 2000;275:26765-26771.
7. phox -containing NADPH oxidase. Circ Res 2001;89:47-54.
8. Zhou J, Schmid T, Brüne B: Tumor necrosis factor-α causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-κB-dependent pathway. Mol Biol Cell 2003;14:2216-2225.
9. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-rastransformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-3331.
10. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L: Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 2001;276:22368-22374.
11. Chen EY, Mazure NM, Cooper JA, Giaccia AJ: Hypoxia activates a platelet-derived growth factor receptor/ phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001;61:2429-2433.
12. Jiang BH, Zheng JZ, Aoki M, Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000;97:1749-1753.
13. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible factor 1? expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-1545.
14. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Bürgel T: Normoxic induction of the hypoxia-inducible factor-1α??by insulin and interleukin-1β?involves the phosphatidylinositol 3-kinase pathway. FEBS Letters 2002;512:157-162.
15. Alvarez-Tejado M, Alfranca A, Aragonés J, Vara A, Landazuri MO, del Peso L: Lack of evidence for the involvement of the phoshoinositide 3-kinase/akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 2002;277:13508-13517.
16. Arsham AM, Plas DR, Thompson CB, Simon MC: Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 2002;277:15162-15170.
17. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E: Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000;275:21695-21702.
18. Milanini J, Vinals F, Pouyssegur J, Pages G: p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998;273:18165-18172.
19. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274:32631-32637.
20. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS: The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000;60:4873-4880.
21. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C: ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000;468:53-58.
22. El Awad B, Kreft B, Wolber E-M, Hellwig-Burgel T, Metzen E, Fandrey J, Jelkmann W: Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000;58:43-50.
23. Wolff M, Jelkmann W: Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 1993;66:27-31.
24. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-159.
25. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ: Effect of ascorbate on the activity of hypoxia inducible factor (HIF) in cancer cells. Cancer Res 2003;63:1764-1768.
26. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363-369.
27. Hur E, Chang KY, Lee E, Lee S-K, Park H: Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol Pharmacol 2001;59:1216-1224.
28. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J: Mitogen-activated protein kinase (MAPK) signaling up-regulates the activity of hypoxia inducible factors by its effects on p300. J Biol Chem 2003;278:14013-14019.
29. Sandau K, Fandrey J, Brüne, B.: Accumulation of HIF-1α under the influence of nitric oxide. Blood 2001;97:1009-1015.
30. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F, Makuuchi M, Esumi H: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001;276:2292-2298.
31. Sandau KB, Faus HG, Brune B: Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000;278:263-267.
32. Sandau KB, Zhou J, Kietzmann T, Brune B: Regulation of the hypoxia-inducible factor 1a by the inflammatory mediators nitric oxide and tumor necrosis factor-a in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 2001;276:39805-39811.
33. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-1262.
34. Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, Gotley D: Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997;157:1482-1486.
35. Grone HJ: Angiogenesis and vascular endothelial growth factor (VEGF): is it relevant in renal patients? Nephrol Dial Transplant 1995;10:761-763.
36. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000;58:2390-2399.
37. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001;159:599-608.
38. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448-1457.
39. Kitamoto Y, Matsuo K, Tomita K: Different response of urinary excretion of VEGF in patients with chronic and acute renal failure. Kidney Int 2001;59:385-386.
40. Kanellis J, Fraser S, Katerelos M, Power DA: Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000;278:F905-F915.